REHOVOT, Israel, June 23, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that ...

Purple Biotech Ltd. has presented new preclinical data on its innovative CAPTN-3 tri-specific antibody platform at the 2025 Annual Congress of the European Association for Cancer Research.

Contribution of NK cells engager arm and conditionally activated T cell engager demonstrated Cleavable capping technology confines therapeutic activity to the local tumor micro environment which ...